Vancouver, British Columbia–(Newsfile Corp. – March 4, 2021) – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)(“Izotropic“), a company developing high-resolution 3D dedicated breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers, is pleased that the American Medical Association (AMA) has released six Category III CPT billing codes for Breast CT technology.
The AMA issuance of these initial insurance billing codes spotlights dedicated breast CT as a promising emerging technology. It is an important development and step in the reimbursement process and aligns with Izotropic’s activities in working with payors to secure future coverage.
Izotropic’s imaging technology is based on technology from Dr. John M. Boone’s laboratory at UC Davis, with prototype devices used in a number of fully-funded clinical trials, the results of which have been published in peer reviewed literature. Izotropic is now engaged with key payors in the USA to define their acceptance criteria and the timelines involved in obtaining coverage for breast CT. Payors may use Dr. Boone’s historic and ongoing breast CT imaging clinical trial data in addition to Izotropic’s future clinical data to support insurance coverage decisions.
Izotropic continues to work towards commercializing its breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancers. The AMA issuance of these initial insurance billing…